Treatment of advanced extranodal NK/T cell lymphoma, nasal-type and aggressive NK-cell leukemia

International Journal of Hematology

Volumn 92, Issue 5, 2010, Pages 697-701

  Suzuki, Ritsuro ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

l asparaginase; Natural killer cell lymphoma; Treatment

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ASPARAGINASE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; GLYCOPROTEIN P; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; PREDNISONE; VINCRISTINE;

ADVANCED CANCER; AGGRESSIVE NK CELL LEUKEMIA; ARTICLE; BLOOD CLOTTING DISORDER; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RESISTANCE; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG SAFETY; DRUG TREATMENT FAILURE; HUMAN; IN VITRO STUDY; MULTIPLE CYCLE TREATMENT; NK T CELL LYMPHOMA; OVERALL SURVIVAL; PANCREATITIS; RADIATION DOSE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; DEXAMETHASONE; DRUG THERAPY, COMBINATION; ETOPOSIDE; HUMANS; IFOSFAMIDE; KILLER CELLS, NATURAL; LEUKEMIA, T-CELL; LYMPHOMA, EXTRANODAL NK-T-CELL; METHOTREXATE; TREATMENT OUTCOME;

EID: 78751581966     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-010-0726-2     Document Type: Article

References (34)

1. ES Jaffe 1996 Classification of natural killer (NK) cell and NK-like T-cell malignancies Blood 87 1207 1210 1:CAS:528:DyaK28XhtVGnt7s%3D 8608206
2. K Oshimi 2003 Leukemia and lymphoma of natural killer lineage cells Int J Hematol 78 18 23 12894846 10.1007/BF02983235
3. R Suzuki K Takeuchi K Ohshima S Nakamura 2008 Extranodal NK/T-cell lymphoma: diagnosis and treatment cues Hematol Oncol 26 66 72 18283711 10.1002/hon.847
4. Chan JKC, Quintanilla-Martinez L, Ferry JA. Peh S-C. Extranodal NK/T-cell lymphoma, nasal type. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 285-8.
5. Chan JKC, Jaffe ES, Ralfkiaer E, Ko Y-H. Aggressive NK-cell leukemia. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC; 2008. p. 276-7.
6. M Yamaguchi K Kita H Miwa K Nishii K Oka T Ohno, et al. 1995 Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells Cancer 76 2351 2356 1:STN:280:DyaK283itlaqsw%3D%3D 8635042 10.1002/1097-0142(19951201)76: 11<2351::AID-CNCR2820761125>3.0.CO;2-1
7. M Egashira N Kawamata K Sugimoto K Oshimi 1999 P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833 Blood 93 599 606 1:CAS:528:DyaK1MXjsleqtw%3D%3D 9885221
8. C Trambas Z Wang M Cianfriglia G Woods 2001 Evidence that natural killer cells express mini P-glycoproteins but not classic 170 kDa P-glycoprotein Br J Haematol 114 177 184 1:CAS:528:DC%2BD3MXmtVyis70%3D 11472365 10.1046/j.1365-2141.2001.02885.x
9. RI Fisher ER Gaynor S Dahlberg MM Oken TM Grogan EM Mize, et al. 1993 Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma N Engl J Med 328 1002 1006 1:STN:280:DyaK3s7ps1Kmtg%3D%3D 7680764 10.1056/NEJM199304083281404
10. W Yong W Zheng Y Zhang J Zhu Y Wei D Zhu J Li 2003 l-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma Int J Hematol 78 163 167 1:CAS:528:DC%2BD3sXnsFChurk%3D 12953813 10.1007/BF02983387
11. M Yamaguchi R Suzuki YL Kwong WS Kim Y Hasegawa K Izutsu, et al. 2008 Phase I study of dexamethasone, methotrexate, ifosfamide, l-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia Cancer Sci 99 1016 1020 1:CAS:528:DC%2BD1cXlslCrt7w%3D 18294294 10.1111/j.1349-7006.2008.00768.x
12. A Jaccard B Petit S Girault F Suarez R Gressin JM Zini, et al. 2009 l-Asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature Ann Oncol 20 110 116 1:STN:280:DC%2BD1M%2Fns12ktA%3D%3D 18701429 10.1093/annonc/mdn542
13. CS Chim SY Ma WY Au C Choy AK Lie R Liang, et al. 2004 Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the international prognostic index Blood 103 216 221 1:CAS:528: DC%2BD2cXhsFGitg%3D%3D 12933580 10.1182/blood-2003-05-1401
14. J Lee C Suh YH Park YH Ko SM Bang JH Lee, et al. 2006 Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study J Clin Oncol 24 612 618 16380410 10.1200/JCO.2005.04.1384
15. R Suzuki J Suzumiya M Yamaguchi S Nakamura J Kameoka H Kojima, et al. 2010 Prognostic factors for mature natural killer (NK)-cell neoplasms: aggressive NK-cell leukemia and extranodal NK-cell lymphoma, nasal-type Ann Oncol 21 1032 1040 1:STN:280:DC%2BC3c3ptFymtw%3D%3D 19850638 10.1093/annonc/mdp418
16. R Liang D Todd TK Chan E Chiu A Lie YL Kwong, et al. 1995 Treatment outcome and prognostic factors for primary nasal lymphoma J Clin Oncol 13 666 670 1:STN:280:DyaK2M7ptVGitA%3D%3D 7884427
17. MMC Cheung JKC Chan WH Lau W Foo PT Chan CS Ng, et al. 1998 Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients J Clin Oncol 16 70 77 1:STN:280:DyaK1c7gtFKktw%3D%3D 9440725
18. YX Li PA Coucke JY Li DZ Gu XF Liu LQ Zhou, et al. 1998 Primary non-Hodgkin's lymphoma of the nasal cavity: prognostic significance of paranasal extension and the role of radiotherapy and chemotherapy Cancer 83 449 456 1:STN:280:DyaK1czlt1yntQ%3D%3D 9690537 10.1002/(SICI)1097-0142(19980801)83: 3<449::AID-CNCR13>3.0.CO;2-W
19. K Kawa 2003 Diagnosis and treatment of Epstein-Barr virus-associated natural killer cell lymphoproliferative disease Int J Hematol 78 24 31 12894847 10.1007/BF02983236
20. R Suzuki 2005 Leukemia and lymphoma of natural killer cells J Clin Exp Hematop 45 51 70 10.3960/jslrt.45.51
21. K Nagafuji T Fujisaki F Arima K Ohshima 2001 l-Asparaginase induced durable remission of relapsed nasal NK/T-cell lymphoma after autologous peripheral blood stem cell transplantation Int J Hematol 74 447 450 1:STN:280:DC%2BD38%2FmslCntg%3D%3D 11794702 10.1007/BF02982090
22. K Obama M Tara K Niina 2003 l-Asparaginase-based induction therapy for advanced extranodal NK/T-cell lymphoma Int J Hematol 78 248 250 14604284 10.1007/BF02983802
23. Y Matsumoto K Nomura Y Kanda-Akano Y Fujita M Nakao K Ueda, et al. 2003 Successful treatment with Erwinia l-asparaginase for recurrent natural killer/T cell lymphoma Leuk Lymphoma 44 879 882 1:CAS:528:DC%2BD3sXitVKhtL4%3D 12802930 10.1080/1042819031000067873
24. M Ando K Sugimoto T Kitoh M Sasaki K Mukai J Ando, et al. 2005 Selective apoptosis of natural killer-cell tumours by l-asparaginase Br J Haematol 130 860 868 1:CAS:528:DC%2BD2MXhtFegtLzF 16156856 10.1111/j.1365-2141.2005.05694.x
25. JP Pinheiro J Boos 2004 The best way to use asparaginase in childhood acute lymphatic leukaemia-still to be defined? Br J Haematol 125 117 127 15059133 10.1111/j.1365-2141.2004.04863.x
26. CH Pui WE Evans 2006 Treatment of acute lymphoblastic leukemia N Engl J Med 354 166 178 1:CAS:528:DC%2BD28XisFWksQ%3D%3D 16407512 10.1056/NEJMra052603
27. Jaccard A, Gachard N, Coppo P, Morschhauser F, Galicier L, Ysebaert L, et al. A prospective phase II trial of an l-Asparaginase containing regimen in patients with refractory or relapsing extranodal NK/T-cell lymphoma. Blood 2008; 112:217a (Abstract #579).
28. Y Yazawa T Takagi S Asakura K Suzuki Y Kano 1999 Effects of 4-hydroperoxy ifosfamide in combination with other anticancer agents on human cancer cell lines J Orthop Sci 4 231 237 1:STN:280:DyaK1M3pvFKnug%3D%3D 10370165 10.1007/s007760050098
29. M Akutsu Y Furukawa S Tsunoda T Izumi K Ohmine Y Kano 2002 Schedule-dependent synergism and antagonism between methotrexate and cytarabine against human leukemia cell lines in vitro Leukemia. 16 1808 1817 1:CAS:528:DC%2BD38XmsV2lsLg%3D 12200697 10.1038/sj.leu.2402573
30. Yamaguchi M, Kwong Y, Maeda Y, Hashimoto C, Kim W, Suh C, et al. Phase II study of SMILE chemotherapy for newly-diagnosed stage IV, relapsed or refractory extranodal NK/T-cell lymphoma, nasal type: NKTSG study. J Clin Oncol 2010; 28:584s (Abstract #8044).
31. R Suzuki J Suzumiya S Nakamura S Aoki A Notoya S Ozaki, et al. 2004 Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells Leukemia 18 763 770 1:STN:280: DC%2BD2c7ltFyquw%3D%3D 14961041 10.1038/sj.leu.2403262
32. Y Nakashima H Tagawa R Suzuki S Karnan K Karube K Ohshima, et al. 2005 Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma/leukemia: Different genomic alteration patterns of aggressive NK-cell leukemia and extranodal NK/T-cell lymphoma, nasal type Genes Chromosomes Cancer 44 247 255 1:CAS:528:DC%2BD2MXhtFSrsrvE 16049916 10.1002/gcc.20245
33. AG Freud MA Caligiuri 2006 Human natural killer cell development Immunol Rev 214 56 72 1:CAS:528:DC%2BD28XhtlClsr7P 17100876 10.1111/j.1600-065X.2006. 00451.x
34. MA Caligiuri 2008 Human natural killer cells Blood 112 461 469 1:CAS:528:DC%2BD1cXpsVajtb0%3D 18650461 10.1182/blood-2007-09-077438